Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 138.8% in December

by · The Markets Daily

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 1,311,773 shares, an increase of 138.8% from the December 15th total of 549,299 shares. Currently, 3.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 171,382 shares, the days-to-cover ratio is currently 7.7 days. Based on an average daily trading volume, of 171,382 shares, the days-to-cover ratio is currently 7.7 days. Currently, 3.6% of the shares of the stock are short sold.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Quadrature Capital Ltd purchased a new stake in Eupraxia Pharmaceuticals during the 2nd quarter worth approximately $61,000. TCI Wealth Advisors Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth about $65,000. Integrated Wealth Concepts LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at $71,000. Bank of America Corp DE boosted its stake in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Eupraxia Pharmaceuticals by 593.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after buying an additional 16,017 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on EPRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, October 8th. Leede Financial upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Cantor Fitzgerald lifted their target price on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday. Wall Street Zen raised shares of Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Eupraxia Pharmaceuticals in a report on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eupraxia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $14.33.

View Our Latest Stock Analysis on EPRX

Eupraxia Pharmaceuticals Stock Down 1.0%

Shares of EPRX stock traded down $0.09 during mid-day trading on Friday, hitting $8.69. 42,638 shares of the stock were exchanged, compared to its average volume of 175,363. The company has a market cap of $312.31 million, a PE ratio of -9.91 and a beta of 1.21. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $8.89. The firm has a fifty day moving average of $6.80 and a 200 day moving average of $5.98.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. Equities analysts predict that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

Featured Articles